FDA Approves Lymphoseek for Pediatric Melanoma, Rhabdomyosarcoma, and Other Solid Tumors

Source: OncLive, June 2021

The FDA approved the radiopharmaceutical agent technetium Tc 99m tilmanocept injection (Lymphoseek) for accurate and precise lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma, and other types of solid tumors.1

“This new indication opens the door for physicians, oncologists and nuclear medicine specialists to more accurately stage the spread of disease using lymphatic mapping in pediatric cancer patients," Tiffany Olson, president of Nuclear & Precision Health Solutions at Cardinal Health, stated in a press release.

READ THE ORIGINAL FULL ARTICLE